Last reviewed · How we verify
Imbruvica
Imbruvica, marketed by Rabin Medical Center, is a treatment for chronic graft-versus-host disease. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following patent expiry.
At a glance
| Generic name | Imbruvica |
|---|---|
| Also known as | Ibrutinib, JNJ-54179060 |
| Sponsor | Rabin Medical Center |
| Target | Nuclear receptor subfamily 4 group A member 3, Platelet glycoprotein VI, Serine/threonine-protein kinase LATS1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Chronic graft-versus-host disease
- Chronic lymphoid leukemia, disease
- M lymphoplasmacytic
- Malignant lymphoma - small lymphocytic
- Mantle cell lymphoma
- Marginal zone lymphoma
- Waldenström macroglobulinemia
Common side effects
- Thrombocytopenia
- Diarrhea
- Fatigue
- Musculoskeletal pain
- Neutropenia
- Rash
- Anemia
- Bruising
- Nausea
Serious adverse events
- Pneumonia
- Hemorrhage
- Atrial fibrillation
- Neutropenia
- Arthralgia
- Thrombocytopenia
- Histiocytic sarcoma
Key clinical trials
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma (PHASE1)
- Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia (PHASE2)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma (PHASE2)
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (PHASE3)
- Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery (PHASE1)
- Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Imbruvica CI brief — competitive landscape report
- Imbruvica updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI